drugset / Trial / NCT04856865
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
Timeline
- Start
- 2021-04-20
- Primary completion
- 2022-11-22
- Completion
- 2022-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADP101 | Unknown | 1500 mg | Oral |
| Subject | ADP101 | Unknown | 4500 mg | Oral |